Clinical Trial Update: MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease. [Phase 1, Phase 2]

View source ↗

Summary

MSC303 is being studied as a subcutaneous injection for lupus nephritis and ANCA-associated glomerulonephritis in Phase 1/Phase 2 trials, with recruitment not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Glomerulonephritis
• Lupus Nephritis

Drugs mentioned

• MSC303

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING